Ascletis receives FDA clearance to begin Phase III ASC30 programme

​

Ascletis Pharma has begun a global Phase III clinical programme for its once-daily oral small molecule GLP-1 receptor agonist, ASC30, for chronic weight management, following clearance from the US FDA.

The post Ascletis receives FDA clearance to begin Phase III ASC30 programme appeared first on Hospital Management.

 

Back to the Featured Stories
Ascletis receives FDA clearance to begin Phase III ASC30 programme

Featured Stories

SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant
Phylo and Chugai collaborate to deploy AI platform in drug discovery
KKR to acquire Integer Holdings in $5.7bn all-cash deal
Curium to acquire Lantheus in all-cash deal worth up to $8bn

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us